Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.

[1]  R. Figlin,et al.  The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC). , 2010 .

[2]  Y. Li,et al.  Antibody-specific detection of CAIX in breast and prostate cancers. , 2009, Biochemical and biophysical research communications.

[3]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Belldegrun,et al.  CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. , 2009, The Journal of urology.

[5]  D. Jäger,et al.  Targeted therapy of renal cell carcinoma: Synergistic activity of cG250‐TNF and IFNg , 2009, International journal of cancer.

[6]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[7]  T. Choueiri,et al.  Non-clear cell renal cancer: features and medical management. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  G Antoch,et al.  PET/CT for the staging and follow-up of patients with malignancies. , 2009, European journal of radiology.

[9]  Hans-Peter Lipp,et al.  Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. , 2009, Current drug metabolism.

[10]  S. Signoretti,et al.  Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Lerman,et al.  Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? , 2009, Biochimica et biophysica acta.

[12]  N. Rioux-Leclercq,et al.  Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma , 2008, International journal of cancer.

[13]  L. Qin,et al.  Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma: An Immunohistochemical Study Comparing 2 Antibodies , 2008, The American journal of surgical pathology.

[14]  Stefano Cavalleri,et al.  Mathematical Models for Prognostic Prediction in Patients with Renal Cell Carcinoma , 2008, Urologia Internationalis.

[15]  A. Ravaud,et al.  Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis , 2007, Cancer.

[16]  J. Cheville,et al.  Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Grankvist,et al.  Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma , 2007, BJU international.

[18]  S. Signoretti,et al.  Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. , 2007, Clinical genitourinary cancer.

[19]  A. Belldegrun,et al.  Prospective evaluation of carbonic anhydrase IX (CAIX) as a molecular marker in metastatic renal cell carcinoma , 2007 .

[20]  N. Avril,et al.  Molecular positron emission tomography and PET/CT imaging in urological malignancies. , 2007, European urology.

[21]  C. Supuran,et al.  Carbonic Anhydrase: Its Inhibitors and Activators , 2007 .

[22]  J. Humm,et al.  Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. , 2007, The Lancet. Oncology.

[23]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[24]  C. Ling,et al.  Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole , 2007, Cancer biology & therapy.

[25]  E. Oosterwijk,et al.  Preliminary Analysis of Patients With Progressive Renal Cell Carcinoma Vaccinated With CA9-peptide–Pulsed Mature Dendritic Cells , 2007, Journal of immunotherapy.

[26]  W. Sly,et al.  Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours , 2006, Histopathology.

[27]  C. Supuran,et al.  Targeting tumor-associated carbonic anhydrase IX in cancer therapy. , 2006, Trends in pharmacological sciences.

[28]  J. Pastorek,et al.  Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. , 2006, International journal of oncology.

[29]  Motoyoshi Tanaka,et al.  A Phase I Trial of Vaccination of CA9-Derived Peptides for HLA-A24-Positive Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[30]  I. Ak,et al.  F-18 FDG pet in detecting renal cell carcinoma , 2005, Acta radiologica.

[31]  W. Oyen,et al.  Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response , 2005, Clinical Cancer Research.

[32]  W. Oyen,et al.  Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Signoretti,et al.  Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.

[34]  S. Horvath,et al.  Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. , 2005, The Journal of urology.

[35]  S. Horvath,et al.  Using Protein Expressions to Predict Survival in Clear Cell Renal Carcinoma , 2004, Clinical Cancer Research.

[36]  S. Larson,et al.  Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  J. Schalken,et al.  Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinoma , 2004, Oncogene.

[38]  C. Supuran.  Carbonic Anhydrases: Catalytic and Inhibition Mechanisms, Distribution and Physiological Roles , 2004 .

[39]  R. Kettmann,et al.  Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. , 2004, International journal of oncology.

[40]  C. Lamers,et al.  A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients , 2004, British Journal of Cancer.

[41]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  W. Oyen,et al.  Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  D. Grignon,et al.  Quantification of G250 mRNA expression in renal epithelial neoplasms by real‐time reverse transcription‐PCR of dissected tissue from paraffin sections , 2003, Pathology.

[44]  W. Oyen,et al.  Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  R. Figlin,et al.  Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  A. Harris,et al.  Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c‐erbB2 , 2002, The Journal of pathology.

[48]  W. Oyen,et al.  131I-cG250 monoclonal antibody immunoscintigraphy versus [18F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study , 2002, Nuclear medicine communications.

[49]  A. Scott,et al.  Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity , 2002, Cancer Immunology, Immunotherapy.

[50]  J. Pastorek,et al.  Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours. , 2001, Journal of hepatology.

[51]  R. Figlin,et al.  Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. , 2001, Cancer research.

[52]  W. Sly,et al.  Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. , 2001, The American journal of pathology.

[53]  W. Sly,et al.  Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours , 2000, Histochemistry and Cell Biology.

[54]  R. Brakenhoff,et al.  Molecular cloning and immunogenicity of renal cell carcinoma‐associated antigen G250 , 2000, International journal of cancer.

[55]  W. Sly,et al.  Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. , 2000, The American journal of pathology.

[56]  C. Figdor,et al.  The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. , 1999, Cancer research.

[57]  W. Oyen,et al.  Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  S. Larson,et al.  Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  J. Pastorek,et al.  Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. , 1998, The American journal of pathology.

[60]  M. Juweid,et al.  Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 , 1997, Cancer Immunology, Immunotherapy.

[61]  W. Oyen,et al.  Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  R. Kettmann,et al.  Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. , 1996, Genomics.

[63]  I. Bernstein,et al.  Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. , 1996, Cancer research.

[64]  M. Lindstrom,et al.  Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[65]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  G. Griffiths,et al.  The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[67]  N. Bander,et al.  Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  D. Ruiter,et al.  Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidney , 1986, International journal of cancer.

[69]  J. Pouysségur,et al.  Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. , 2009, Cancer research.

[70]  A. Scott,et al.  A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. , 2007, Cancer immunity.

[71]  P. Mulders,et al.  A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. , 2006, The Journal of urology.